Sam Brusco, Associate Editor02.15.22
GE Healthcare has received European Medicines Agency (EMA) approval for further imaging modalities using its Rapiscan stress agent. It’s already used in SPECT MPI for adults. It’s now approved for use in MRI, CT, and PET scans.
Rapiscan mimics the effects of exercise in hearts of adult patients unable to exercise, aiding in coronary artery disease diagnosis. Rapiscan’s use with an MR contrast agent in stress cardiac magnetic resonance imaging (CMR) helps assess the heart’s function and blood flow so clinicians can perform a single stress/rest/MRI protocol.
Dr. Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan told the press: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”
Dr. Mark Hibberd, chief medical officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorization of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”
GE Healthcare has the rights to promote Rapiscan excluding U.S., Mexico, and Canada.
Rapiscan mimics the effects of exercise in hearts of adult patients unable to exercise, aiding in coronary artery disease diagnosis. Rapiscan’s use with an MR contrast agent in stress cardiac magnetic resonance imaging (CMR) helps assess the heart’s function and blood flow so clinicians can perform a single stress/rest/MRI protocol.
Dr. Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan told the press: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”
Dr. Mark Hibberd, chief medical officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorization of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”
GE Healthcare has the rights to promote Rapiscan excluding U.S., Mexico, and Canada.